Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Starts Phase II Study of ArtemiC to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"K S Kim International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGC Signs Multi-Country Distribution Agreement for Anti-Infective Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Expands ArtemiC\u2122 Phase II Clinical Trial on COVID-19 Patients in Israel and India","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Malta Enerprises","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"$3.7 million","newsHeadline":"MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MGC Pharma Gets CDSCO Approval to Import its Nanoparticle Micellar Formulation, CimetrA for Testing to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Swiss PharmaCan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Sciensus Rare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Hempstreet","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Oberon Capital","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"MGC Pharma Launches Share Purchase Plan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by MGC Pharmaceuticals

    Menu

    MGC Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MGC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharma Launches Share Purchase Plan

              Details:

              The proceeds will be used for production, raw material and laboratory costs associated with production of GMP cannabinoid medicines CannEpil, a high-CBD, low-THC formulation delivered by an oral mucosal solution and CogniCann, an oral spray that combines THC and CBD.

              Lead Product(s): Cannabidiol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: CannEpil

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oberon Capital

              Deal Size: $2.6 million Upfront Cash: Undisclosed

              Deal Type: Financing August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              HempStreet Announces Partnership with MGC Pharma to Revolutionise Global Phytomedicine Sector

              Details:

              Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.

              Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

              Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Hempstreet

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer's in the EU and UK

              Details:

              The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer's disease.

              Lead Product(s): Cannabidiol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: CannEpil

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sciensus Rare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COVID

              Details:

              The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three times daily for 6 weeks.

              Lead Product(s): Artemisinin,Curcumin,Frankincense

              Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Swiss PharmaCan

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharma Gets CDSCO Approval to Import its Nanoparticle Micellar Formulation, CimetrA for Testing to Treat Covid-19

              Details:

              MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswellia.

              Lead Product(s): Curcumin,Boswellia Serrata

              Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharmaceuticals Receives Cash Grant to Help Establish ArtemiCTM Productioninn Malta

              Details:

              The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.

              Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

              Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Malta Enerprises

              Deal Size: $3.7 million Upfront Cash: $3.7 million

              Deal Type: Funding December 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharmaceuticals Provides ArtemiCTM Phase II Clinical Trial Results Update

              Details:

              Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.

              Lead Product(s): Artemisinin,Curcumin,Frankincense

              Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Pharmaceuticals Expands ArtemiC™ Phase II Clinical Trial on COVID-19 Patients in Israel and India

              Details:

              The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.

              Lead Product(s): Artemisinin,Curcumin,Frankincense

              Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Signs Multi-Country Distribution Agreement for Anti-Infective Drug

              Details:

              The Term Sheet stipulates that KS KIM will distribute ArtemiC throughout Israel, Russia, and the Commonwealth of Independent States and the countries of the Balkan region.

              Lead Product(s): ArtemiC

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Undisclosed

              Recipient: K S Kim International

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MGC Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MGC Starts Phase II Study of ArtemiC to Treat Covid-19

              Details:

              The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.

              Lead Product(s): ArtemiC

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY